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Introduction
According to the conventional classification of col-
loid systems, foams (Figure 1) are defined as dis-
continuous gas bubbles dispersed in a continuous 
phase (liquid or solid). Solid foams include thin 
polymer walls, while traditional liquid foams con-
tain thin liquid films separating gas bubble ag-
glomerations [1]. Foams can also be described as 
deformed (laminar difform) lyosols because the 
dispersing phase is a colloid. The thickness of the 
lamellae separating the bubbles is in the micro-
nanometer range [2].
There are non-aqueous foams too, which with-
out the increase in the liquid phase viscosity, gell-
ing, or solidification caused by cooling or polym-
erization are only stable for a short time. Due to 
their low density, good heat-insulating ability, and 
great mechanical solidity despite the small weight, 
these solid foams (xerosols, xerogels) are of great 
industrial significance in several areas, including 
pharmaceutical industry [2]. Gelatine or collagen-
based solid foams, or sponges, containing antibi-
otic or steroid active ingredients are often used as 
primary wound dressings [3]. The mutual attri-
bute of all foams that distinguishes them from 
sponges, irrespectively of the state of the film, is 
the enclosed bubbles and the lack of connection 
with the surrounding bubbles, so the gas phase is 
discontinuous while the liquid or solid phase is 
continuous [1].
Foam formation
Foams can be produced by two basic methods. The 
more common, mechanical one is by dispersing 
the gas phase in the liquid with beating or shaking 
[2]. The other way is by the gas-supersaturation of 
the liquid. The gas can be dissolved under pres-
sure that is later released or can be formed in situ 
[4]. In both cases, the lifetime of the foams made of 
pure liquids is quite short [2]. For an enduring dis-
persion, the presence of surface active agents ab-
sorbing spontaneously onto the interface is essen-
tial. These amphipathic molecules have polar 
groups that contact with the water and also a hy-
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Abstract
Foams are becoming more and more popular in several areas of our lives, including pharmaceutics and cosmetics. They are colloid sys-
tems where gas is dispersed in a liquid phase. Active ingredient bearing pharmaceutical foams are traditionally applied topically (der-
mal, local rectal, vaginal), but formulations for other delivery routes (e.g. nanosystems parenterally, solid foams orally) are also avail-
able. Numerous advantages are attached to foams when compared to traditional vehicles, resulting in increased patient compliance. 
Amongst others, the suitable composition contributes to quick, oily residue free and convenient application even on large or hairy ar-
eas, as well as to good drug transfer rate.
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Figure 1 Aerosol foam (A); propellant-free foam (B); solid 
polypropylene foam particles (C); stucture of a gum based 
solid foam (D)
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drophobic part that orients towards the gas and so 
creating a monomolecular layer. Surfactants re-
duce the energy required for foam formulation by 
decreasing the surface tension. They also foster the 
creation of an elastic boundary layer thus increas-
ing the lamella stability by inhibiting their taper-
ing. This progress can be hindered in different 
ways: by the presence of hydration shell of the sur-
factant molecules or by the repulsion of the ionic 
surfactant’s electric charges. Another way is by the 
bulking of partially solvating particles, that reduce 
the system’s free energy with the amount of adhe-
sion work (Wa), at the interface [2,5].
𝑊𝑊! = 𝛾𝛾 ∙ 𝑎𝑎! ∙ 𝜋𝜋 ∙ 1± cos  𝜃𝜃 !  (1)
where γ is the surface tension, a is the radius of 
the particle and θ is the contact angle [2].
Aerosol foams are formed due to the overpressure 
(usually 2-4 bars) when upon actuation the pro-
pellant evaporates quickly from the liquid. De-
layed foam formulation can be reached by using a 
propellant with a high boiling point [6].
Foam stability
Due to the excess interfacial Helmholtz free ener-
gy, the foams are thermodynamically unstable but 
can have kinetic stability in case of hampered 
phase disunion [5].
Ensuring good stability is essential for effective 
foam forming. Without decent firmness, the struc-
ture is to break down partially resulting in in-
creased bubble sizes. There are several events oc-
curring simultaneously in foams that influence 
their stability.
Liquid evaporation itself can destroy the foam 
structure. The type of the surfactant used can in-
fluence the speed by altering the nature of the 
monolayer and result in reduced evaporation [7].
It is known, that the smaller volume phase has 
higher vapor pressure and better solubility. As a re-
sult of the difference in the vapor pressure of vari-
ous sized bubbles, the smaller ones disappear grad-
ually. This is called Ostwald ripening or dispropor-
tionation and it can also be affected by the nature of 
the monolayer or the type of gas used. The more 
water-soluble gas results in less stable foams, since 
it is transported quicker across the films [7,8].
Owing to buoyancy force, in a few minutes after 
foam forming a creamy layer is observable on top 
of the liquid phase. Creaming is slower in concen-
trated dispersions. 
Cream ing and drainage 
lead to the break-down 
of foams. Curved liquid 
surface results in lower 
Laplace pressure (curva-
ture pressure, capillary 
pressure) in the middle 
than around. This capil-
lary downdraft results in 
decreased water volume in the foam and causes the 
thinning of the liquid film. When the dispersed vol-
ume fraction is about 60%, the bubbles deform each 
other resulting in a polyhedral foam. The lamellae 
meet each other at 120-degree angles, forming a 
channel called Plateau border (Figure 2) [2,4,7].
The lifetime of foams can be elongated by in-
creasing the viscosity of the liquid phase by add-
ing e.g. polymers [2]. It is known, that even thick 
foam films can be stabilized by a low concentra-
tion polymer-surfactant complex. Given higher 
concentrations, uneven film thickness can be ob-
served due to the aggregated complexes [9].
Medicated foams
The European Pharmacopoeia defines medicated 
foams (musci medicati) as preparations for skin or 
mucosal applications that consist of large volumes 
of gas dispersed in a liquid. They usually contain 
one or more active ingredients, surfactants for foam 
formation and other excipients. The liquid formula-
tion is filled into a pressurized container that is 
equipped with a valve suitable for the ex tempore 
foam formation at the site of application [10].
The composition of the foam formulation, the 
type and amount of propellant highly influence 
the properties of the foams. The properties of an 
ideal medicated foam from the perspective of the 
patient:
 − the easy application even on bigger, hirsute or 
sensitive, inflamed areas,
 − stable and does not collapse, or drain for a short 
period post-expelling,
 − persist while manipulation – e.g. lifting off a 
surface with an applicator for application on the 
skin,
 − good spreadability – low shear is enough to de-
stroy, thus slight rubbing is sufficient,
 − drug delivery ability at least as good as conven-
tional transdermal formulations,
 − less oily residues than creams, ointments, [11]
 − easy removal, in case it is needed,
Figure 2 The structure of 
Plateau border
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 − non-irritant, non-toxic, non-allergenic, pharma-
cologically inert vehicle.
The drug transfer rate of foams is influenced by 
the significant physicochemical changes that the 
formulation undergoes while and after actuation 
from the container. When topically applied, the 
quick evaporation of the propellant causes in-
creased active ingredient concentration, in some 
cases even supersaturation, that increases the ab-
sorption rate of foams [12].
A couple of pharmaceutical foams are available 
in Hungary and foreign countries and their indica-
tions for use are listed in Table I [11,12].
Classification of foams
In the field of pharmaceutics and cosmetics, the 
most used foams belong to aerosol foams, that are 
pressurized semi-solid formulations in aerosol 
cans.
Table I Some examples of medicated foam formulations
Active pharmaceutical 
ingredient Indication Product examples
azelaic acid mild to moderate rosacea Finacea® Foam (Bayer)
betamethasone valerate corticosteroid sensitive scalp dermato-sis
Luxiq® (Stiefel Laboratories Inc.). Beta-
methasone valerate 0.12% Topical Foam 
(Mylan N.V.)
budesonide colitis ulcerosa
Budenofalk® (Dr. Falk Pharma GmbH), 
UCERIS® Rectal Foam (Salix Pharmaceuti-
cals Inc.)
calcipotriene plaque psoriasis (adults) Sorilux® (Mayne Pharma)
calcipotriol, betamethasone psoriasis (adults) Enstilar® (LEO Pharma)
clindamycin acne vulgaris (above 12 years) Evoclin® (Stiefel Laboratories Inc.)
clobetazol propionate plaque psoriasis (above 12 years) Olux® (Stiefel Laboratories Inc.)
common witch hazel ex-
tract, α-bisabolol decubitus
TEVACARE antidecubitus foam spray 
(Laboratorium Dr. Deppe)
desonide atopic dermatitis Verdeso® (Aqua Pharmaceuticals)
dexpanthenol, bisabolol, 
Vitamin A, E and F sunburn, skin irritation Panthenol Foam (Dr. Müller Pharma)
dexpanthenol, lidocaine, 
sodium sulfosalicilate sa-
marate
superficial burns, running sores Phlogosam (PannonPharma Kft.)
hydrocortisone colitis ulcerosa Colifoam® (Meda Pharmaceuticals)
hydrocortisone acetas adjuvant therapy of ulcerative proctitis Cortifoam® (Alaven Pharmaceutical LLC)
hydrocortisone, pramoxine inflamed, itchy manifestations of corti-costeroid sensitive dermatosis EpiFoam
® (Alaven Pharmaceutical LLC)
ketoconazole seborrhoeic dermatitis (above 12 years) Extina
® (Stiefel Laboratories Inc.), Ketocon-
azole Foam 2% (Perrigo Company Plc)
minoxidil alopecia Minoxidil Topical (Publix Super Markets Inc)
pramoxine, hydrocortisone
temporary relief of rectal inflammation, 
itching, pain, and swelling associated 
with hemorrhoids, fissures, cryptitis, 
proctititis
ProctoFoam®-HC (Alaven Pharmaceutical 
LLC)
sodium fluoride caries protection Oral-B® Minute-Foam® (Procter & Gamble Co.)
sodium sulfacetamide seborrhoeic dermatitis, seborrhea sicca Ovace® Plus (Espada Dermatology)
tolnaftate tinea pedis, tinea corporis FungiFoam® (The Tetra Corporation)
2QR bio-active bacterial 
blocker chicken pox PoxClin
® (TRIMB HealthCare)
— cleansing, restoring and protecting skin Tena Wash Mousse (Essity Hygiene and Health AB)
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Foams can be classified in several ways. We can 
differentiate aqueous, hydroethanolic and emol-
lient foams as well as petrolatum-, oil- or other 
solvent-based foams too [13].
Emollient foams, as traditional creams or lo-
tions, are emulsion-based so have a soothing, 
moisturizing effect. O/W or W/O emulsions can be 
used for the formulation, where the oil phase con-
sists of mineral oil, triglyceride, fatty acid esters, 
such as isopropyl myristate, or isopropyl palmi-
tate, or essential oil. Omega-3 and 6 oils can also 
be used for therapy, or silicone oils for their pro-
tective nature. Rarely petrolatum is used, but for 
its greasy, cloth-staining properties. Emollient 
foams are complicated systems, even a small 
change in the composition can lead to the destabi-
lization of the foam [14]. At body temperature, 
they are relatively stable, but the easy application 
on large target area is guaranteed by shear force 
breakability.
Foams formed from nanoemulsions (droplet 
size between 20 and 200 nm) are promising for-
mulations given their ability to increase the bio-
availability and efficacy of hard-to-dissolve active 
ingredients by solubilizing them.
Hydroalcoholic (hydroethanolic) foams contain 
about 60% ethanol amongst others. Alcohol pro-
motes better skin penetration of active ingredients 
compared to other vehicles. It alters the barrier 
properties of stratum corneum reversibly thus en-
hancing the penetration. The quick evaporation of 
alcohol from the skin results in fast drying of the 
foam, therefore it leaves a less unpleasant sticky 
feeling behind. Rapid evaporation also contributes 
to the thermolabile property of hydroalcoholic 
foams, discouraging dispensing foam onto the 
hands instead of directly to the target area. Owing 
to the undesired skin-drying property of alcohols, 
the application of these foams is limited. In addi-
tion, skin irritation was reported repeatedly. 
These side effects lead to the creation of a foam 
that contains alcohol and still has an emollient ef-
fect (e.g. ScyteraTM prepared coal tar 2% w/w 
foam).
Water-free foams that enable water-insoluble or 
unstable active ingredients to be used in the form 
of foams are also under development. The formu-
lation would prevent microorganism growth, 
making preservatives unnecessary and could 
maximize the emollient effect [13].
Foam formulations containing aprotic, polar 
solvents, as dimethyl sulfoxide (DMSO) are under 
investigation. DMSO is a potent solvent, used as a 
penetration enhancer as it carries drugs through 
membranes without damage. According to labora-
tory studies, DMSO blocks peripheral nerve C fi-
bers; thus the analgesic effect is attributed to it. 
Anti-inflammatory, antioxidant and membrane 
stabilizing properties promote DMSO-containing 
foams beneficial in the treatment of numerous dis-
eases [15].
Amongst aerosol foams two- and three-phase 
foams can be differentiated (Figure 3A). By the 
fore-mentioned, the liquefied propellant is dis-
solved under high pressure in the mixture of the 
solvent, the surfactant, and the stabilizing agent. 
In three-phase foams, the propellant is dissolved 
in the inner phase of an oil-in-water type emul-
sion. In this case, the emulsifier and foaming agent 
could be the same, and vaporized propellant acts 
as the third phase. Shaking before use is required 
in the course of both the two- and three phase 
foams [6].
Figure 3 Scheme for two- and three phase foams in aerosol 
cans (A); propellant-free pump device (B)
Figure 4 Determination of duration of expansion
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Excipients
Various functional excipients (summarized in Ta-
ble II) are necessary for the preparation of medi-
cated foams. The use of foaming agents, or stabiliz-
ers, that can be surface active agents, macromolec-
ular substances that are easily solvated or partial-
ly wetting powders is inevitable. [2]. When decid-
ing on the surfactant several factors have to be 
considered. Although ionic agents are effective 
they are known skin irritants; consequently, the 
use of non-ionic surfactants is suggested, especial-
ly when inflamed areas are to be treated [14].
Pharmaceutically acceptable oils, like mineral 
oils, plant oils or triglycerides are mostly chosen 
as hydrophobic component. Skin protective silicone 
oils are also preferred, while the greasy petrola-
tum is less used. Omega-3, Omega-6 polyunsatu-
rated oils or other therapeutically beneficial oils 
are proven to work even well [14].
Tests, examinations
The European Pharmacopoeia lists three tests for 
medicated foams: relative foam density, duration 
of expansion and sterility. The first one is deter-
mined by the m/e ratio, where m is the mass of the 
foam in grams and e is the mass of the same vol-
ume water in grams. It is sufficient if from three 
measurements the deviation of the values not ex-
ceeds 20% from the mean value.
Duration of expansion is determined in a bu-
rette with specified parameters (Figure 4). After 
thorough shaking the volume of the actuated ca. 
30 ml foam is read every 10 seconds until it reach-
es the maximum volume. It is sufficient if from 
three measurements none exceeds 5 minutes [10].
Information from the quality of foam can be 
gained by examining its temporal behavior 
through time. The reduction of the foam volume 
can be measured as well as the half lifetime, that is 
the time it takes the volume of the foam to be 
halved. Other than these static methods, station-
ary ones can also be used. In the latter case, it is 
possible to characterize the foaming agent and the 
foam itself together. For this a specific device is 
needed – foaming is induced by streaming gas 
with constant speed through a perforated mem-
brane and the stationary foam volume is mea-
sured when the speed of foam forming and break-
down is equal [2].
There are several tests beyond the pharmaco-
poeial ones. The circumstances of use are imitated, 
so the tests are carried out with the lack of propel-
lant, as it evaporates quickly after actuation [13].
Examining the physical properties of foams, 
like macroscopic appearance, bubble size, foam 
viscosity and elasticity, is inevitable.
A stereo microscope with digital ocular enables 
the observation of bubble size and the structure of 
the foam. With image analysis bubble size distribu-
tion, as well as several descriptive parameters (like 
Feret diameter, area, circularity or roundness) of in-
dividual bubbles, like the number of bubbles can be 
determined. Texture analysis is another method to 
gain information from the foam structure.
For basic evaluation of foams several methods 
can be used, including the determination of foam 
expansion (FE [%]), foam liquid stability (FLS 
[%]), foam volume stability (FVS [%]) and gas 
fraction (GF [ml]). These tests provide data on 
foamability and foam stability [6]. It is important 
to note, that there is no explicit connection be-
tween these two parameters [3].
The following parameters can be determined by 
filling up a glass cylinder with the foam and re-
cording the initial and the aged volume as well as 
the volume of drained liquid over time.
Table II Excipients for liquid foams
Solvent distilled water, ethanol, isopropanol, glycerine, propylene glycol, di-methyl isosorbide, DMSO
Foaming agent cetyl alcohol, cetyl stearyl alcohol, sodium docecyl sulfate, sodium ole-ate, sodium stearate, stearic acid, polysorbate 20
Foam stabiliser
xanthan gum, guar gum, hydroxyethyl cellulose, hydroxypropyl cel-
lulose, hydroxypropyl methylcellulse methyl cellulose, agar-agar, 
alginates, sodium lauryl sulfate, lauryl acid, palmitic acid, stearic acid, 
coconut oil, tragachant gum, gelatine, glycerine
Hydrophobic component, emollient mineral oils, plant oils, esters (e.g. isopropyl myristate), essential oils, petrolatum, omega-3 polyunsaturated oil, silicon oil
Absorption promoter ethanol, fatty acids, fatty alcohols
Foam breaker alkyl polysiloxanes, oils, alcohols, fatty alcohols, acetone
Antifoaming agent silicone oil, glycerides, polyamide
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𝐹𝐹𝐹𝐹 % =
𝑉𝑉!"#$ − 𝑉𝑉!"#$%&'()"*
𝑉𝑉!"#$%&!"#$%
∙ 100%  (2)
where Vformulation is the volume of the formulation 
[ml] required to produce Vfoam [ml]. A linear rela-
tionship can be found between FE and good foam-
ability.
Foam liquid stability can be calculated as follows:
𝐹𝐹𝐹𝐹𝐹𝐹 % =
𝑉𝑉!"#$"% ,!"!"#
𝑉𝑉!"#$%&!"#$%
∙ 100%  (3)
where Vliquid,30min is the volume of drained liquid af-
ter 30 min [ml]. Lower FLS value refers to better 
stability.
Foam volume stability can be determined by us-
ing equation (4).
𝐹𝐹𝐹𝐹𝐹𝐹 % =
𝑉𝑉(𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓!"!"#)
𝑉𝑉!"#$
∙ 100%  (4)
where Vfoam,30min is the foam volume after 30 min 
[ml]. There is an inverse relationship between FVS 
and foam stability [6].
Gas fraction, as well as bubble size, vary in wide 
range depending on the way of application [3]. For 
the calculation of GF, the following equation is to 
be used:
𝐺𝐺𝐺𝐺 = 𝑉𝑉!"#$ − 𝑉𝑉!"#$%&'()"*   (5).
Turbiscan method, based on Faraday-Tyndall 
effect, provides another method for the determi-
nation of foam stability. The light scattering of col-
loid solutions is measurable by measuring the in-
tensity of transmitted and backscattered light, that 
are influenced by the amount of air in the foam. 
Important to note, that the values vary in time due 
to foam destabilization.
Carrying out rheological measurements on 
foams is also circumstantial as for their instability. 
Oscillatory mode enables the determination of the 
film elasticity [6].
After dispensing foams, over time, they tend to 
collapse. Analyzing photos taken periodically can 
provide information about the time it takes the 
height of the foam to be halved. This foam col-
lapse time is to be determined at 36 ˚C. It should 
take more than 1 minute, so proper application is 
possible, but 2-3 minutes is ideal [13].
Characterizing quick-breaking foams, due to 
their short lifetime, with the above-mentioned 
methods is complicated. In these cases, cryo-SEM 
(cryogenic scanning electron microscopy) is an al-
ternative method for quantitative foam analysis. 
Information can be gained aside from morpholog-
ical parameters, also from bubble size, and bubble 
size distribution. For these examinations, the foam 
has to be quickly frozen with liquefied nitrogen 
and fractured by a precision rotary knife [16].
Krüss Gmbh. has developed a dynamic foam 
analyser (DFA100) for the scientific analysis of liq-
uid foams. The instrument precisely measures the 
height of foams, and with the help of the software 
(ADVANCE, Krüss Gmbh.) data on foam stability, 
foamability, as well as decay characteristics can be 
easily obtained. It also enables the quick analysis 
of bubble size and bubble size distribution by 
measuring the liquid content. These features ease 
the optimization of all kinds of liquid foams, in-
cluding pharmaceutical ones [17].
Dermal foams
Dermatological preparations on the market are 
mainly creams, gels or ointments. However, in the 
last decades the interest in new vehicles, including 
foams, has significantly increased. This promising 
formulation is the objective of numerous patents, 
so it is highly likely that in a couple of years a 
growing number of foam preparations will be 
found in the market amongst the traditional phar-
maceutical forms [16].
The first known dermatological application of 
foams belongs to Woodford and Barry. They ex-
amined the therapeutic advantages of a quick-
breaking hydroethanolic foam containing beta-
methasone benzoate compared to traditional 
semi-solid formulations. They reported it effective 
in psoriasis treatment [18]. Another study report-
ed that a calcipotriol and betamethasone dipropi-
onate-bearing foam reduced the symptoms signif-
icantly better than the ointment studied [19].
Based on several other studies foams are prov-
en to be at least as effective and safe as other der-
mal dosage forms with similar compositions. Pa-
tients – regardless of sex, age or ethnicity – consid-
ering other properties also prefer foams over tra-
ditional formulations [13,18–21].
In case of active ingredients with poor water 
solubility, foam formulations are advantageous, 
because with dissolving them in the oil phase of 
an emulsion foam, higher bioavailability can be 
reached [13].
Dermal foams, usually containing topical corti-
costeroids, are mainly used in the treatment of 
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skin and scalp dermatoses, like eczema, psoriasis 
or seborrhoea [12]. According to pharmacopoeial 
directions, foams have to be sterile when they are 
used on severely injured skin areas or open 
wounds [10].
In community pharmacies in Hungary two rele-
vant medicated foams for dermal use are available. 
Phlogosam (PannonPharma Kft.), sold without 
prescription, containing dexpanthenol, lidocaine 
and sodium samarium disulfosalicylate anhydrate 
for first and second-degree superficial burn, der-
matitis solaris or arteficialis and eczema [22].
TEVACARE antidecubitus foam spray is an 
emulsion foam containing common witch-hazel 
extract and α-bisabolol. In addition to the skin 
nourishing and regenerating properties, it has 
cleansing and deodorizing effect. The foam layer 
helps in even distribution of the mechanical pres-
sure thus reducing decubitus prevalence [23].
Rectal foams
In the European Pharmacopoeia, the definition of 
rectal preparations is ‘intended for rectal use in 
order to obtain a systemic or local effect, or they 
may be intended for diagnostical purposes’ [24]. 
Local administration is for the adstringent or 
desinficient effect, but more often steroid-bearing 
foams are used for the treatment of inflammatory 
rectal diseases (Chron disease, colitis ulcerosa). 
Beyond the advantages of rectal administrations, 
rectal foams have several other favourable proper-
ties. On the contrary to suppositories, active in-
gredient liberates without a latency time form the 
foam. As they gently fill the rectum, they provide 
a larger area for absorption. When applied no irri-
tation is experienced derived from the solidity 
and shape of suppositories. Compared to rectal 
solutions (klysmae), the application is significantly 
easier and more convenient, backflow is less likely.
Foam formulations provide good alternative for 
the rectal application of light and/or oxidation-
sensitive active ingredients, as can be stored un-
der pressure in a dark container.
As a disadvantage, their low density can be 
mentioned, for the reason that large API quanti-
ties cannot be administered due to the limited vol-
ume of rectum [25,26].
In 2009, Dr. Falk Pharma GmbH released Bude-
nofalk® 2 mg rectal foam. This budesonide-con-
taining preparation for the treatment of colitis ul-
cerosa, is the first and so far the only rectal foam 
on the market in Hungary [22].
Vaginal and intrauterine foams
Vaginal foams containing spermicides are used as 
local anticoncipients. There are also vaginal tab-
lets and ovulum, that foams when in contact with 
cervical mucus. All three compositions are ad-
ministered precoital. These contraceptive meth-
ods are preferred for their effectivity and the lack 
of contraindications, but in some cases, local irri-
tation was reported. The inconvenience of applica-
tion is also disadvantageous [27–29].
Antibiotic-bearing foams are also patented for 
the treatment of vaginal infections [30].
Intrauterine foams containing antibiotics or dis-
infectants are used in veterinary therapy of endo-
metritis. The gas produced by the effervescent re-
action (Figure 5), that helps the homogenous dis-
tribution of the active ingredient, as large volume 
of foam is formed [31].
Dry foams
In 1974 the effect of a gentamicin-bearing anti-in-
fective dry foam was investigated on Pseudomonas 
aeruginosa bacteria. Compared with an ointment, 
they were found to have the same efficacy [32].
Dry foam technology was developed as an al-
ternative method to improve the solubility and 
bioavailability of active ingredients. A foam for-
mulated from the suspension of the drug was 
dried under determined circumstances and tablet-
ted after granulation. This method was proven to 
have better solubility and bioavailability com-
pared to direct compress tablets or wet granulated 
tablets [33,34].
Figure 5 Foam expansion from effervescent intrauterine 
tablet (A) and the structure of the foam formed (B)
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Foam dressings
Over the years, a wide variety of wound dressings 
appeared on the market for the different wound 
types. An ideal dressing helps rapid healing while 
conveniently worn by the patient.
Foam dressings, made of porous polyurethane, 
have high moisture vapour transmission rate and 
provide moist, warm circumstances ideal for 
wound healing. Due to the foam structure, foam 
dressings have good absorbent properties that en-
able their use for heavily exuding wounds (Figure 
6) [35,36].
In a broad sense, some surgical implants can 
also be categorised as foams. There are collagen-
based gentamicin-impregnated foam implants 
that can promote the healing of chronic and post-
operative wounds by encouraging the wound 
healing process of the human organism. They en-
sure local antibiotic concentration higher than the 
MBC (minimal bactericide concentration) while 
keeping the systemic level below toxic [36,37].
DepoFoam
DepoFoam® is a sustained-release, lipid-based 
multivesicular drug delivery system applied in 
the form of injections. The name is based on struc-
tural similarities with foams, only here the parti-
cles contain several internal aqueous chambers 
separated by a non-concentric continuous network 
of biocompatible and biodegradable lipid mem-
branes. This unique structure results in high 
aqueous-volume – liquid ratio (95:5). Subsequent-
ly, high drug loading and encapsulation capacity 
for therapeutic proteins, peptides and water-solu-
ble drugs are provided.
Compared to traditional liposomes DepoFoam® 
particles are larger. The great size (1100 µm) in-
hibits quick clearance by tissue macrophages and 
results in depot formation, from where the active 
ingredient release is sustained without a ‘burst’ ef-
fect. The release profile can be altered by changes 
in the composition.
The technology was successfully applied with 
several active ingredients, like interleukins, IGF, 
insulin, colony stimulating factors and different 
peptides. DepoCyt® is a clinically investigated in-
trathecal injection containing cytarabine for the 
treatment of malignant lymphomatous meningi-
tis, while DepoDurTM is a morphine-bearing epi-
dural injection for reducing postoperative pain 
[38–41].
Advantages
Foams offer a modern alternative in topical treat-
ment. Owing to their good spreadability, fast ab-
sorption and easy application (even on large or 
hirsute areas), foams are preferred to creams or 
ointments. As rubbing in is not required, the ap-
plication on sore, inflamed skin areas is painless. 
Furthermore, the emulsion-based emollient foams 
can also assist to the hydration of the skin without 
leaving oily residues and greasy feeling. These 
contribute to patient acceptance and enhanced 
compliance and adherence [12,13,42].
Image analysis of foams
With picture analysis software (ImageJ, public do-
main program inspired by NIH, US) from photos 
or microscopic images, data can be gained from 
the shape, size and size distribution of the bubbles 
in foams. It enables the examination of the effect 
of the composition on the structure of the foam, or 
to follow the structural changes in time.
Figure 7A shows a picture (Olympus Stylus 
TG-4 digital camera, Olympus Corp., Japan) of a 
foam consisting of 5% w/w Labrasol® (Gattefossé, 
France) and distilled water (DW) formed with a 
propellant-free foam pump device (Figure 3 B, 100 
ml, PET from Nordtek Imexco Kft., Hungary). Im-
Figure 7 Photo of 5% w/w Labrasol® – DW foam before (A) 
and after analysis (B)
Figure 6 Gentamycin containing foam wound dressing (A) 
and its microscopic structure (B)
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age analysis was accomplished from a 0,5x0,5 mm 
photo section (Figure 7 B). The results are shown 
in Table III Spanvalue was calculated as follows:
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 =
𝐷𝐷! ,  !.! − 𝐷𝐷! ,  !.!
𝐷𝐷! ,    !.!
  (6)
where Dv,0.9: 90% of the particles are under this di-
ameter, Dv,0.1: 10% of the particles are under diam-
eter, Dv,0.5: 50% of the particles are under this di-
ameter.
The bubble size data gained from image analysis 
enables the determination of bubble size distribu-
tion. Drawing frequency distribution (%) over the 
cumulative bubble size diameter (dmin; mm) re-
sults in the cumulative bubble size distribution 
graph (Figure 8).
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